KPV vs Larazotide
Reviewed by the BestHealingPeptides Editorial Team ·
KPV and larazotide are both studied for gut-barrier indications but operate at completely different points in the mucosal pathology cascade. KPV suppresses NF-κB-driven inflammatory cytokine release inside mucosal cells; larazotide blocks zonulin-receptor signalling at the apical tight junction. The two are mechanistically complementary rather than substitutes — and one has progressed to Phase IIb clinical trials while the other has not.
KPV
A three-amino-acid C-terminal fragment of α-MSH studied for its anti-inflammatory effects in colitis, atopic skin conditions, and mucosal healing models — without the pigmentary effects of full-length MSH.
Larazotide
An eight-amino-acid synthetic peptide functioning as a tight-junction regulator and zonulin antagonist. Designed for luminal delivery with minimal systemic absorption, larazotide has been investigated in multiple Phase II trials for coeliac disease with persistent symptoms, and represents the furthest-advanced clinical programme for a peptide targeting intestinal barrier function.
| Aspect | KPV | Larazotide |
|---|---|---|
| Size | 3 amino acids (~342 Da) | 8 amino acids (~726 Da) |
| Mechanism | Intracellular NF-κB pathway suppression | Apical-surface zonulin-receptor antagonism |
| Delivery | Oral via HA-nanoparticle encapsulation (research); also topical for dermal models | Oral capsule (clinical-trial route); minimal systemic absorption |
| Clinical evidence | Pre-clinical only | Phase IIb in coeliac disease with persistent symptoms (Leffler 2015) |
| Principal research model | DSS/TNBS murine colitis | Gliadin-challenge models and coeliac patients |
| WADA status | Not listed | Not listed |
Mechanism — where each acts in the mucosal cascade
KPV (Lys-Pro-Val), the C-terminal tripeptide of α-MSH, acts intracellularly to suppress NF-κB-driven transcription of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) in intestinal epithelial cells and infiltrating immune cells. Its molecular target is not a surface receptor but the NF-κB pathway components downstream of TLR and cytokine-receptor signalling. Larazotide acts extracellularly at the apical surface of intestinal epithelial cells as an antagonist of the zonulin-receptor signalling system that opens tight junctions in response to gliadin and other stimuli. The two therefore intervene at different stages of the same mucosal pathology: barrier opening (larazotide) and downstream inflammatory amplification (KPV).
Evidence depth — research vs clinical
Larazotide has progressed substantially further in clinical development than KPV. Multiple Phase I and Phase II clinical trials in coeliac disease, including a 342-subject Phase IIb (Leffler et al., Gastroenterology 2015) showing significant reductions in gastrointestinal symptom scores in coeliac patients with persistent symptoms on a gluten-free diet, provide the most extensive human safety dataset of any healing-focused research peptide. KPV's evidence is overwhelmingly pre-clinical, dominated by DSS- and TNBS-induced colitis models in rodents and atopic dermatitis cell-culture studies. The Laroui et al. 2013 hyaluronic-acid nanoparticle delivery work transformed oral KPV from near-zero exposure to therapeutically relevant mucosal concentrations.
Delivery — both face oral-bioavailability challenges differently
KPV is rapidly degraded by luminal and brush-border peptidases unless encapsulated; the established research delivery platform is hyaluronic-acid nanoparticles that protect the peptide and concentrate delivery at the colonic mucosa. Larazotide is designed from inception for luminal action with minimal systemic absorption — its principal pharmacological feature is that it does not appreciably enter the systemic circulation, which is the basis of its favourable safety profile. Larazotide is therefore administered as a simple oral capsule; KPV requires the encapsulation platform.
Regulatory and accessibility
Neither peptide is licensed as a medicine in the UK. Larazotide has a defined sponsor with an active development programme; KPV is studied largely in academic settings without a commercial development pathway. Both are available as research chemicals; larazotide-grade material for clinical-trial-equivalent work is more controlled.
When to choose which
Choose KPV for mucosal-inflammation research where NF-κB-driven cytokine release is the principal mechanistic hypothesis — DSS/TNBS colitis, atopic dermatitis, dermal inflammation. Choose larazotide for tight-junction and intestinal-permeability research, particularly in coeliac-disease-adjacent models. For combined-mechanism research, both can be used together — they intervene at different stages of the same pathology cascade and have no known pharmacological interaction.
Verdict
KPV and larazotide are mechanistically complementary, not interchangeable. Larazotide is the further-advanced compound with clinical-trial-grade evidence; KPV remains primarily a research-stage anti-inflammatory tripeptide. For combined gut-barrier research models, both can be used together to address barrier opening and downstream inflammation in the same protocol.
Where to source research peptides for laboratory research
The following UK-based suppliers stock research-grade, lyophilised peptides for in-vitro and pre-clinical work. Purity and provenance vary; always request a Certificate of Analysis (CoA) and confirm cold-chain storage on arrival. None of the products linked below are approved for human use.
- PeptideAuthority.co.uk
UK-based research peptide supplier with batch certificates of analysis and >99% purity testing.
- PeptideBarn.co.uk
Wide catalogue of research-grade lyophilised peptides shipped from the UK, including bulk vials.